Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Step in Style: A Survey of \Solace and Execution on the Track\ Running Shoes - 2Man threatens attack on German high-speed train, 12 lightly injured
- 3Amid growing bipartisan scrutiny of Pete Hegseth, Trump says he 'wouldn't have wanted … a second strike' on alleged Venezuelan drug boat survivors
- 4Vote in favor of your Number one kind of juice
- 5Key Caper d: A Survey of \Procedure and Tomfoolery Released\ Tabletop game
- Significant Elements to Consider Prior to Applying for a Mastercard: 6 Vital Contemplations
- A Republican elected governor in California? It's not as far-fetched as it sounds.
- The most effective method to Guarantee Scholastic Honesty in Web-based Degrees
- Find the Future of Outsourcing: Exploring the Gig Economy
- Holocaust survivor, descendants urge High Court to allow Gaza children medical access
- 23 Most Amusing Messages At any point Sent Among Youngsters and Their Folks
- NASA's giant moon rocket, in photos
- An Investigate of 6 Creative Specialty Mixed drinks
- Lucky airplane passengers capture NASA's Artemis 2 moon launch from the sky
